First Time Loading...

Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 47.865 USD 1.62% Market Closed
Updated: May 20, 2024

Net Margin
Janux Therapeutics Inc

-762.4%
Current
-952%
Average
-8.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-762.4%
=
Net Income
-55.6m
/
Revenue
7.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Janux Therapeutics Inc
NASDAQ:JANX
2.5B USD
-762%
US
Abbvie Inc
NYSE:ABBV
291B USD
11%
US
Amgen Inc
NASDAQ:AMGN
167.8B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108.7B USD
29%
AU
CSL Ltd
ASX:CSL
134.3B AUD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
84.7B USD
2%
US
Moderna Inc
NASDAQ:MRNA
54B USD
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
US
Biogen Inc
NASDAQ:BIIB
33.7B USD
12%
KR
Celltrion Inc
KRX:068270
38.7T KRW
25%
Janux Therapeutics Inc
NASDAQ:JANX
Country US
Market Cap 2.5B USD
Net Margin
-762%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 291B USD
Net Margin
11%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 167.8B USD
Net Margin
13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 115.5B USD
Net Margin
39%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 108.7B USD
Net Margin
29%
CSL Ltd
ASX:CSL
Country AU
Market Cap 134.3B AUD
Net Margin
17%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 84.7B USD
Net Margin
2%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 54B USD
Net Margin
-116%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Net Margin
-33%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 33.7B USD
Net Margin
12%
Celltrion Inc
KRX:068270
Country KR
Market Cap 38.7T KRW
Net Margin
25%

Profitability Report

View the profitability report to see the full profitability analysis for Janux Therapeutics Inc.

Full Profitability Report

See Also

Summary
JANX intrinsic value, competitors valuation, and company profile.
DCF Valuation
JANX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JANX stock valuation using valuation multiples.
Wall Street Estimates
JANX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JANX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-762.4%
=
Net Income
-55.6m
/
Revenue
7.3m
What is the Net Margin of Janux Therapeutics Inc?

Based on Janux Therapeutics Inc's most recent financial statements, the company has Net Margin of -762.4%.

ALPHA SPREAD
Join more than 139,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.